SCHEMBL7903079

SCHEMBL7903079

CC(=O)O[C@@H](C(=O)Nc1ccc(-c2noc(=O)[nH]2)cc1)[C@H]1OCCN(c2cc(F)cc(C(=O)N3CCCC3)c2)C1=O

nearest known ligand 0.36

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
RARA P10276 1/20 0.36
PLA2G2A P14555 1/20 0.36
CPT1A P50416 1/20 0.36
CPT1B Q92523 1/20 0.36
F9 P00740 9/20 0.35
RBP4 P02753 1/20 0.35
HRH1 P35367 1/20 0.34
CCR3 P51677 1/20 0.34
F11 P03951 4/20 0.33
KLKB1 P03952 4/20 0.33
XDH P47989 2/20 0.32
SLC22A12 Q96S37 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12547650 0.99 RARA (0.36) RARAPLA2G2ACPT1ACPT1BF9
SCHEMBL12547195 0.95 F9 (0.40) RARAPLA2G2ACPT1ACPT1BF9
SCHEMBL12547712 0.93 F9 (0.39) RARAPLA2G2ACPT1ACPT1BF9
SCHEMBL12548073 0.92 F9 (0.39) RARAPLA2G2ACPT1ACPT1BF9
SCHEMBL7907457 0.92 RARA (0.39) RARACPT1ACPT1BF9F11
SCHEMBL7895080 0.90 F9 (0.39) RARAPLA2G2ACPT1ACPT1BF9
SCHEMBL12547214 0.89 F9 (0.39) RARAPLA2G2ACPT1ACPT1BF9
SCHEMBL12547188 0.89 F9 (0.45) RARAPLA2G2ACPT1ACPT1BF9
SCHEMBL12548044 0.88 F9 (0.39) RARAPLA2G2ACPT1ACPT1BF9
SCHEMBL12546776 0.88 F9 (0.48) RARAPLA2G2ACPT1ACPT1BF9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373634-B1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARM CO LTD (JP) 2015-11-11 EP disclosed
US-8987242-B2 Morpholinone compounds as factor IXA inhibitors MERCK SHARP & DOHME CORP. (US) 2015-03-24 US disclosed
US-8987242-B2 Morpholinone compounds as factor IXA inhibitors MERCK SHARP & DOHME CORP. (US) 2015-03-24 US disclosed
US-8642582-B2 Morpholinone compounds as factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2014-02-04 US disclosed
US-8642582-B2 Morpholinone compounds as factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2014-02-04 US disclosed
US-20110135650-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-06-09 US disclosed
US-20110135650-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-06-09 US disclosed
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-10 US disclosed
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-10 US disclosed
WO-2010065717-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110135650-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS SERPINC1, F9, F8 RARA 2636/4885PLA2G2A 2926/4885CPT1A 2971/4885
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS SERPINC1, F9, F8 RARA 2636/4885PLA2G2A 2926/4885CPT1A 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.